The 78.5%-80.7% gross margin band across all ten quarters suggests unit economics on the devices themselves are healthy and stable, but the persistence of operating margins between -33.0% and -48.1% in non-holiday quarters implies SG&A is behaving as a fixed cost base that has not scaled with the revenue contraction seen since 2025. Net margin of -35.0% versus operating margin of -33.0% indicates interest and below-the-line items are now a visible secondary drag after the 2026Q2 debt draw, so adjusted operating margin before stock compensation (roughly $6.5M, or 14% of revenue) is arguably the better gauge of underlying earning power than any reported bottom-line figure.

With coverage negative in nine of ten quarters, any ratio-based solvency test currently reads as distressed not because debt service is unsupportable in absolute terms but because EBIT is negative, meaning the debt appears to have been raised to fund operations or shore up liquidity rather than to leverage a profitable base. The sharp swing suggests leverage is becoming less comfortable, and investors should monitor whether coverage can turn positive on operating recovery or whether the new debt simply extends the runway for continued losses. D/E of 1.07 now sits well above peers such as PRCT at 0.21 and NVCR at 0.85, though below ATEC's 17.21, placing TMCI in the more-levered half of this loss-making device cohort.

Asset turnover of 0.25, unchanged across most of the ten-quarter series, indicates the revenue base is generating little output per dollar of the $181.1M asset pool, so the efficiency problem appears to be demand absorption rather than collection discipline. The DIO figure, while possibly inflated by a single-period inventory build or accounting convention, still points to heavy inventory dependence relative to the 1.95 quick ratio, and combined with DSO trending from 69 to 60 days, suggests the working-capital structure will remain a persistent cash drag unless sell-through improves.

A negative P/E and absent EV/EBITDA mean traditional earnings-based valuation is uninformative, so P/S of 1.35 becomes the operative multiple — modest in absolute terms but set against contracting revenue and a business burning cash, which implies the market is not pricing meaningful growth. P/B of 3.20 looks elevated against peers like OSUR at 0.90 and near ANGO at 2.96 and PRCT at 3.01, but because retained losses are shrinking the denominator (accumulated deficit of -$282.8M), the multiple is inflated by equity erosion rather than by optimistic pricing, warranting further investigation into whether book value continues to shrink faster than any re-rating.